Measurements of the DNA double-strand break response
Abstract
Radiotherapy and some chemotherapeutic drugs kill cancer cells by induction
of the extremely toxic DNA double-strand breaks (DSBs). Measurements of
the DSB response in patients during therapy could allow personalized dosing
to improve tumor response and minimize side effects. DSBs induce a strong
cellular response via phosphorylation of H2AX, P-H2AX and the formation
of foci. P-H2AX can be measured by flow cytometry or counted in separate
cell nuclei by immunofluorescence microscopy. The overall aim of my
research has been to develop and validate methods to measure P-H2AX in
mononuclear cells from cancer patients undergoing radiotherapy.
Initially, we wanted to characterize DNA damage induced by
the chemotherapeutic drug etoposide that induces TopoII-linked DSBs and to
test its ability to activate the P-H2AX response using a flow cytometry-based
P-H2AX assay. We found that only 0.3% of etoposide-induced DSBs
activated the H2AX response and toxicity. We concluded that the P-H2AX
response was a good measure of the toxic effects of etoposide.
Next, we wanted to optimize the flow cytometry assay for
mononuclear cells from cancer patients undergoing radiation therapy. The P-H2AX
response was measured before and after 5Gy pelvic irradiation and in
in vitro-irradiated controls. We found a fraction of cells with high P-H2AX
signals that corresponded to the 5Gy in vitro-irradiated blood controls. This
study indicated that flow cytometry may be well suited for measurements of
the P-H2AX response in mononuclear cells following local radiotherapy.
To be able to implement the P-H2AX assay in clinical practice
and use it in relation to clinical outcome and side effects we have also
developed stable and reliable calibrators based on phosphopeptide-coated
beads and fixed cells. Using these calibrators it could be possible to use the
P-H2AX flow cytometry assay in the clinic in a controlled manner.
Finally, using immunostaining in solution before cells are
mounted on microscopic slides for quantification of single P-H2AX foci by
immunofluorescence, we have the possibility to analyze 16 patient samples
within few hours, which makes this method suitable for clinical use.
Parts of work
I. Numerical analysis of etoposide induced DNA breaks. Muslimović A, Nyström S, Gao Y, Hammarsten O. ::PMID::19516899 II. An optimized method for measurement of gamma-H2AX in blood mononuclear and cultured cells. Muslimovic A, Ismail IH, Gao Y, Hammarsten O. ::PMID::18600224 III. Calibrators for clinical measurements of phosphorylated H2AX in patient cells by flow cytometry. Muslimovic A, Johansson P, Ruetschi U, Hammarsten O. Submitted manuscript. IV. In-solution staining and arraying method for the immunofluorescence detection of γH2AX foci optimized for clinical applications. Johansson P, Muslimovic A, Hultborn R, Fernström E, Hammarsten O. ::PMID:: 21906040
Degree
Doctor of Philosophy (Medicine)
University
University of Gothenburg. Sahlgrenska Academy
Institution
Institute of Biomedicine. Department of Clinical Chemistry and Transfusion Medicine
Disputation
Fredagen den 19 oktober 2012, kl. 13.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborg
Date of defence
2012-10-19
aida.muslimovic@clinchem.gu.se
Date
2012-09-25Author
Muslimovic, Aida
Keywords
DSB response
cancer patients
H2AX phosphorylation
Publication type
Doctoral thesis
ISBN
978-91-628-8504-5
Language
eng